If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...

Recursion is near the start of its growth story. In case you're not familiar, its business has three segments, but only two have any chance of yielding revenue in the near term. The company's ...